Advertisement
Screener

LIGAND PHARMACEUTICALS INCORPORATED (LGND) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants

2.4 / 5 stars · 57/120 Roast Me

LIGAND PHARMACEUTICALS INCORPORATED Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants

LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-24.

Discontinued › Income Statement › Earnings Per Share

us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2021-02-24

  • LIGAND PHARMACEUTICALS INCORPORATED incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2019-09-30 was 0.00 shares, a 100.00% decline year-over-year.
  • LIGAND PHARMACEUTICALS INCORPORATED incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2019-06-30 was 0.00 shares, a 100.00% decline year-over-year.
  • LIGAND PHARMACEUTICALS INCORPORATED incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2019-03-31 was 0.00 shares, a 100.00% decline year-over-year.
  • LIGAND PHARMACEUTICALS INCORPORATED incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2018-09-30 was 1.57M shares, a 3201.43% increase year-over-year.
  • LIGAND PHARMACEUTICALS INCORPORATED incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2020 was 0.00 shares.
  • LIGAND PHARMACEUTICALS INCORPORATED incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2019 was 0.00 shares, a 100.00% decline from fiscal 2018.
  • LIGAND PHARMACEUTICALS INCORPORATED incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2018 was 1.02M shares, a 981.91% increase from fiscal 2017.
  • LIGAND PHARMACEUTICALS INCORPORATED incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2017 was 94.00K shares.
Period endIncremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 monthIncremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month as first filedIncremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 monthIncremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month as first filedIncremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 monthIncremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month as first filedIncremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month
2020-12-310.00 shares
10-K · filed 2021-02-24
2019-12-310.00 shares
10-K · filed 2021-02-24
2019-09-300.00 shares
10-Q · filed 2019-11-08
0.00 shares
10-Q · filed 2019-11-08
2019-06-300.00 shares
10-Q · filed 2019-08-08
0.00 shares
10-Q · filed 2019-08-08
2019-03-310.00 shares
10-Q · filed 2019-05-09
2018-12-311.02M shares
10-K · filed 2021-02-24
2018-09-301.57M shares
10-Q · filed 2019-11-08
1.57M shares
10-Q · filed 2018-11-08
1.08M shares
10-Q · filed 2019-11-08
1.08M shares
10-Q · filed 2018-11-08
2018-06-30982.00K shares
10-Q · filed 2019-08-08
981.81K shares
10-Q · filed 2018-08-08
835.00K shares
10-Q · filed 2019-08-08
835.33K shares
10-Q · filed 2018-08-08
2018-03-31689.00K shares
10-Q · filed 2019-05-09
688.85K shares
10-Q · filed 2018-05-09
2017-12-3194.00K shares
10-K · filed 2020-02-27
2017-09-3047.65K shares
10-Q · filed 2018-11-08
15.88K shares
10-Q · filed 2018-11-08
2017-06-300.00 shares
10-Q · filed 2018-08-08
0.00 shares
10-Q · filed 2018-08-08
2017-03-310.00 shares
10-Q · filed 2018-05-09
2016-12-310.00 shares
10-K · filed 2019-02-28
2016-09-300.00 shares
10-Q · filed 2017-11-09
0.00 shares
10-Q · filed 2017-11-09
2015-12-310.00 shares
10-K · filed 2018-03-01